Koji Yanase

1.9k total citations
38 papers, 1.6k citations indexed

About

Koji Yanase is a scholar working on Hepatology, Molecular Biology and Cancer Research. According to data from OpenAlex, Koji Yanase has authored 38 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 13 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Koji Yanase's work include Liver physiology and pathology (9 papers), Liver Disease Diagnosis and Treatment (9 papers) and Angiogenesis and VEGF in Cancer (9 papers). Koji Yanase is often cited by papers focused on Liver physiology and pathology (9 papers), Liver Disease Diagnosis and Treatment (9 papers) and Angiogenesis and VEGF in Cancer (9 papers). Koji Yanase collaborates with scholars based in Japan. Koji Yanase's co-authors include Hitoshi Yoshiji, Yasuhide Ikenaka, Ryuichi Noguchi, Junichi Yoshii, Hiroshi Fukui, Tadashi Namisaki, Shigeki Kuriyama, Mitsuteru Kitade, Hirohisa Tsujinoue and Hiroo Imazu and has published in prestigious journals such as Hepatology, Journal of Hepatology and International Journal of Cancer.

In The Last Decade

Koji Yanase

38 papers receiving 1.6k citations

Peers

Countries citing papers authored by Koji Yanase

Since Specialization

Citations

This map shows the geographic impact of Koji Yanase's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koji Yanase with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koji Yanase more than expected).

Fields of papers citing papers by Koji Yanase

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koji Yanase. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koji Yanase. The network helps show where Koji Yanase may publish in the future.

Co-authorship network of co-authors of Koji Yanase

This figure shows the co-authorship network connecting the top 25 collaborators of Koji Yanase. A scholar is included among the top collaborators of Koji Yanase based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koji Yanase. Koji Yanase is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats 2013 ·Journal of Gastroenterology ·Kosuke Kaji, Hitoshi Yoshiji, Yasuhide Ikenaka, Ryuichi Noguchi, Yosuke Aihara, Akitoshi Douhara, Kei Moriya, Hideto Kawaratani, Yusaku Shirai, Junichi Yoshii, Koji Yanase, Mitsuteru Kitade, Tadashi Namisaki, Hiroshi Fukui	102
2	Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice 2010 ·Hepatology Research ·Kosuke Kaji, Hitoshi Yoshiji, Mitsuteru Kitade, Yasuhide Ikenaka, Ryuichi Noguchi, Yusaku Shirai, Junichi Yoshii, Koji Yanase, Tadashi Namisaki, Masaharu Yamazaki, Tatsuhiro Tsujimoto, Hideto Kawaratani, Hiroshi Fukui	18
3	The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure 2010 ·PubMed ·Tadashi Namisaki, Hitoshi Yoshiji, Ryuichi Noguchi, Yasuhide Ikenaka, Mitsuteru Kitade, Kosuke Kaji, Yosuke Aihara, (unknown), Koji Yanase, (unknown), Hideto Kawaratani, Yusaku Shirai, (unknown), Hiroshi Fukui	7
4	Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats 2009 ·Journal of Gastroenterology ·Hitoshi Yoshiji, Ryuichi Noguchi, Mitsuteru Kitade, Kosuke Kaji, Yasuhide Ikenaka, Tadashi Namisaki, Junichi Yoshii, Koji Yanase, Masaharu Yamazaki, Tatsuhiro Tsujimoto, Takemi Akahane, Hideto Kawaratani, Masahito Uemura, Hiroshi Fukui	54
5	Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat 2009 ·BMC Research Notes ·Hitoshi Yoshiji, Ryuichi Noguchi, Yasuhide Ikenaka, Tadashi Namisaki, Mitsuteru Kitade, Kosuke Kaji, Yusaku Shirai, Junichi Yoshii, Koji Yanase, Masaharu Yamazaki, Tatsuhiro Tsujimoto, Hideto Kawaratani, Takemi Akahane, Yosuke Aihara, Hiroshi Fukui	47
6	Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis 2008 ·Molecular Medicine Reports ·Mitsuteru Kitade, Hitoshi Yoshiji, Hideyuki Kojima, Yasuhide Ikenaka, Ryuichi Noguchi, Kosuke Kaji, Junichi Yoshii, Koji Yanase, Tadashi Namisaki, Masaharu Yamazaki, Tatsuhiro Tsujimoto, (unknown), Hideto Kawaratani, Takemi Akahane, Hiroshi Fukui	20
7	Leptin‐mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats† 2006 ·Hepatology ·Mitsuteru Kitade, Hitoshi Yoshiji, Hideyuki Kojima, Yasuhide Ikenaka, Ryuichi Noguchi, Kosuke Kaji, Junichi Yoshii, Koji Yanase, Tadashi Namisaki, Kiyoshi Asada, Masaharu Yamazaki, Tatsuhiro Tsujimoto, Takemi Akahane, Masahito Uemura, Hiroshi Fukui	122
8	Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development 2006 ·Hepatology Research ·Hitoshi Yoshiji, Shigeki Kuriyama, Ryuichi Noguchi, Yasuhide Ikenaka, Mitsuteru Kitade, Kosuke Kaji, Junichi Yoshii, Koji Yanase, Masako Yamazaki, (unknown)	30
9	Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression 2005 ·Journal of Hepatology ·Hitoshi Yoshiji, Shigeki Kuriyama, Ryuichi Noguchi, Junichi Yoshii, Yasuhide Ikenaka, Koji Yanase, Tadashi Namisaki, Mitsuteru Kitade, Masaharu Yamazaki, Tsutomu Masaki, Hiroshi Fukui	57
10	Combination of interferon‐β and angiotensin‐converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development 2005 ·Liver International ·Hitoshi Yoshiji, Shigeki Kuriyama, Ryuichi Noguchi, Junichi Yoshii, Yasuhide Ikenaka, Koji Yanase, Tadashi Namisaki, Mitsuteru Kitade, Masaharu Yamazaki, Hirohisa Tsujinoue, Hiroshi Fukui	21
11	Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice 2004 ·Hepatology ·Hitoshi Yoshiji, Shigeki Kuriyama, Junichi Yoshii, Yasuhide Ikenaka, Ryuichi Noguchi, Daniel J. Hicklin, Yan Wu, Koji Yanase, Tadashi Namisaki, Mitsuteru Kitade, Masaharu Yamazaki, Hirohisa Tsujinoue, Tsutomu Masaki, Hiroshi Fukui	85
12	Successful treatment of acute Budd-Chiari syndrome with percutaneous transluminal angioplasty 2004 ·Abdominal Imaging ·Yusaku Shirai, Hitoshi Yoshiji, Masao Fujimoto, Hideyuki Kojima, Koji Yanase, Tadashi Namisaki, Mitsuteru Kitade, Kazuhiko Yamamoto, Hiroshi Sakaguchi, Kimihiko Kichikawa, Hiroshi Fukui	1
13	Two cases of colonic tuberculosis presenting with massive melena 2004 ·International Journal of Clinical Practice ·Tadashi Namisaki, Hitoshi Yoshiji, Masao Fujimoto, Hideyuki Kojima, Koji Yanase, Mitsuteru Kitade, Yasuhide Ikenaka, Masahisa Toyohara, Junichi Yamao, (unknown), (unknown), (unknown), (unknown), Yoshitaka Matsumura, Hiroshi Fukui	6
14	Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats 2004 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·Hitoshi Yoshiji, Ryuichi Noguchi, Shigeki Kuriyama, Yasuhide Ikenaka, Junichi Yoshii, Koji Yanase, Tadashi Namisaki, Mitsuteru Kitade, Tsutomu Masaki, Hiroshi Fukui	124
15	Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development 2004 ·Journal of Hepatology ·Hitoshi Yoshiji, Shigeki Kuriyama, Junichi Yoshii, Yasuhide Ikenaka, Ryuichi Noguchi, Koji Yanase, Tadashi Namisaki, Mitsuteru Kitade, Masaharu Yamazaki, Hirohisa Tsujinoue, Tsutomu Masaki, Hiroshi Fukui	26
16	Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. 2003 ·PubMed ·Ryuichi Noguchi, Hitoshi Yoshiji, Shigeki Kuriyama, Junichi Yoshii, Yasuhide Ikenaka, Koji Yanase, Tadashi Namisaki, Mitsuteru Kitade, Masaharu Yamazaki, Akira Mitoro, Hirohisa Tsujinoue, Hiroo Imazu, Tsutomu Masaki, Hiroshi Fukui	57
17	Tissue inhibitor of metalloproteinases‐1 (TIMP‐1) inhibits tumor growth and angiogenesis in the TIMP‐1 transgenic mouse model 2003 ·International Journal of Cancer ·Yasuhide Ikenaka, Hitoshi Yoshiji, Shigeki Kuriyama, Junichi Yoshii, Ryuichi Noguchi, Hirohisa Tsujinoue, Koji Yanase, Tadashi Namisaki, Hiroo Imazu, Tsutomu Masaki, Hiroshi Fukui	92
18	Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma 2002 ·Hepatology ·Hitoshi Yoshiji, Shigeki Kuriyama, Junichi Yoshii, Yasuhide Ikenaka, Ryuichi Noguchi, Daniel J. Hicklin, James Huber, Toshiya Nakatani, Hirohisa Tsujinoue, Koji Yanase, Hiroo Imazu, Hiroshi Fukui	126
19	Inhibition of renin–angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats 2002 ·Journal of Hepatology ·Hitoshi Yoshiji, Junichi Yoshii, Yasuhide Ikenaka, Ryuichi Noguchi, Hirohisa Tsujinoue, Toshiya Nakatani, Hiroo Imazu, Koji Yanase, Shigeki Kuriyama, Hiroshi Fukui	81
20	Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse 2002 ·Hepatology ·Hitoshi Yoshiji, Shigeki Kuriyama, Junichi Yoshii, Yasuhide Ikenaka, Ryuichi Noguchi, Toshiya Nakatani, Hirohisa Tsujinoue, Koji Yanase, Tadashi Namisaki, Hiroo Imazu, Hiroshi Fukui	191

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact